{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:51:59Z","timestamp":1791827519401,"version":"4.3.4"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jval.2026.06.014","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:01:54Z","timestamp":1784044914000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Modeling Systemic Lupus Erythematosus Treatment Cost-Effectiveness Based on a Novel Lupus Low Disease Activity State Treat-to-Target Approach"],"prefix":"10.1016","author":[{"given":"Maria","family":"Farris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Golder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dante","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric F.","family":"Morand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"Nikpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rangi","family":"Kandane-Rathnayake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Will","family":"Sierakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Tilden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai Wai","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jval.2026.06.014_bib1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update on the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jval.2026.06.014_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jval.2026.06.014_bib3","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2665-9913(19)30105-5","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study","volume":"2","author":"Apostolopoulos","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.jval.2026.06.014_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000157","article-title":"Independent association of glucocorticoids with damage accrual in SLE","volume":"3","author":"Apostolopoulos","year":"2016","journal-title":"Lupus Sci Med"},{"issue":"Suppl 1","key":"10.1016\/j.jval.2026.06.014_bib5","doi-asserted-by":"crossref","first-page":"i22","DOI":"10.1093\/rheumatology\/keac678","article-title":"Dilemma of immunosuppression and infection risk in systemic lupus erythematosus","volume":"62","author":"He","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.jval.2026.06.014_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2023.101873","article-title":"Systemic lupus erythematosus and glucocorticoids: a never-ending story?","volume":"37","author":"Paredes-Ruiz","year":"2023","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.jval.2026.06.014_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s40674-017-0069-8","article-title":"The risk benefit ratio of glucocorticoids in SLE: have things changed over the past 40 years?","volume":"3","author":"Stojan","year":"2017","journal-title":"Curr Treatm Opt Rheumatol"},{"issue":"1","key":"10.1016\/j.jval.2026.06.014_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000590","article-title":"Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies","volume":"8","author":"Ugarte-Gil","year":"2021","journal-title":"Lupus Sci Med"},{"issue":"9","key":"10.1016\/j.jval.2026.06.014_bib9","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1136\/annrheumdis-2013-205171","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort","volume":"74","author":"Bruce","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jval.2026.06.014_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/acr.25528","article-title":"2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis","author":"Sammaritano","year":"2025","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jval.2026.06.014_bib11","first-page":"8","article-title":"DORIS definition of remission in SLE: final recommendations from an international task force","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"issue":"4","key":"10.1016\/j.jval.2026.06.014_bib12","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"10.1016\/j.jval.2026.06.014_bib13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.42392","article-title":"A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus","volume":"75","author":"Kalunian","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.jval.2026.06.014_bib14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jval.2026.06.014_bib15","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ard.2025.01.016","article-title":"LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials","volume":"84","author":"Morand","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.jval.2026.06.014_bib16","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/ard-2022-222748","article-title":"Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus","volume":"82","author":"Morand","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.jval.2026.06.014_bib17","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a lupus low disease activity state (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jval.2026.06.014_bib18","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/S2665-9913(19)30037-2","article-title":"Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study","volume":"1","author":"Golder","year":"2019","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.jval.2026.06.014_bib19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13075-017-1256-6","article-title":"Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study","volume":"19","author":"Golder","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.jval.2026.06.014_bib20","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1016\/S2665-9913(22)00304-6","article-title":"Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study","volume":"4","author":"Kandane-Rathnayake","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"10.1016\/j.jval.2026.06.014_bib21","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2665-9913(24)00121-8","article-title":"Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study","volume":"6","author":"Golder","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"10.1016\/j.jval.2026.06.014_bib22","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/acr.24023","article-title":"Lupus low disease activity state and reduced direct health care costs in patients with systemic lupus erythematosus","volume":"72","author":"Yeo","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"Suppl 5","key":"10.1016\/j.jval.2026.06.014_bib23","doi-asserted-by":"crossref","first-page":"v19","DOI":"10.1093\/rheumatology\/keaa420","article-title":"Treatment targets in SLE: remission and low disease activity state","volume":"59","author":"Golder","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.jval.2026.06.014_bib24","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1093\/rheumatology\/keaa120","article-title":"Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-na\u00efve patients with systemic lupus erythematosus","volume":"59","author":"Gao","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.jval.2026.06.014_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140843","article-title":"Assessment of the economic impact of Belimumab for the treatment of systemic lupus erythematosus in the Italian setting: a cost-effectiveness analysis","volume":"10","author":"Pierotti","year":"2015","journal-title":"PLOS One"},{"key":"10.1016\/j.jval.2026.06.014_bib26","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/704207","article-title":"Health technology assessment of Belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus","volume":"2014","author":"Specchia","year":"2014","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.jval.2026.06.014_bib27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.vhri.2021.06.007","article-title":"A systematic review of the economic evaluations of Belimumab in systemic lupus erythematosus","volume":"27","author":"Petrou","year":"2022","journal-title":"Value Health Reg Issues"},{"issue":"sup1","key":"10.1016\/j.jval.2026.06.014_bib28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/13696998.2024.2318996","article-title":"The economic burden of systemic lupus erythematosus in United Arab Emirates","volume":"27","author":"Alansari","year":"2024","journal-title":"J Med Econ"},{"key":"10.1016\/j.jval.2026.06.014_bib29","doi-asserted-by":"crossref","first-page":"S254","DOI":"10.1016\/j.jval.2018.04.1716","article-title":"Belimumab for the treatment of adults living with active systemic lupus erythematosus: a cost-effectiveness analysis in Canada","volume":"21","author":"Mursleen","year":"2018","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2026.06.014_bib30","first-page":"161","article-title":"Cost-effectiveness analysis of Belimumab in patients with systemic lupus erythematosus in Spain","volume":"39","author":"D\u00edaz-Cerezo","year":"2015","journal-title":"Farm Hosp"},{"issue":"sup1","key":"10.1016\/j.jval.2026.06.014_bib31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/13696998.2024.2320603","article-title":"Microsimulation model of the cost-effectiveness of anifrolumab compared to Belimumab in the United Arab Emirates","volume":"27","author":"Elsisi","year":"2024","journal-title":"J Med Econ"},{"issue":"1","key":"10.1016\/j.jval.2026.06.014_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2019-000350","article-title":"Generating evidence to inform health technology assessment of treatments for SLE: a systematic review of decision-analytic model-based economic evaluations","volume":"7","author":"Gavan","year":"2020","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.jval.2026.06.014_bib33","first-page":"118","article-title":"A systematic literature review and critical appraisal of economic modelling approaches of pharmacologic interventions for systemic lupus erythematosus (SLE)","volume":"3","author":"Tolley","year":"2018","journal-title":"Pharmacoeconomics: Open Access"},{"key":"10.1016\/j.jval.2026.06.014_bib34","series-title":"Belimumab for treating active autoantibody-positive systemic lupus erythematosus. Technology appraisal guidance [TA752]","year":"2021"},{"key":"10.1016\/j.jval.2026.06.014_bib35","series-title":"Public Summary Document: Anifrolumab (Saphnelo\u00ae), Solution Concentrate for I.V. Infusion 300 mg in 2 mL \u2013 July 2022 PBAC Meeting","year":"2022"},{"key":"10.1016\/j.jval.2026.06.014_bib36","series-title":"Public Summary Document: Anifrolumab (Saphnelo)","year":"2023"},{"issue":"3","key":"10.1016\/j.jval.2026.06.014_bib37","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/art.1780390303","article-title":"The development and initial validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for systemic lupus erythematosus","volume":"39","author":"Gladman","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.jval.2026.06.014_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000761","article-title":"Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials","volume":"10","author":"Bruce","year":"2023","journal-title":"Lupus Sci Med"},{"issue":"5","key":"10.1016\/j.jval.2026.06.014_bib39","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1136\/ard-2022-222748corr1","article-title":"Correction: Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus","volume":"83","author":"Morand","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jval.2026.06.014_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/annrheumdis-2023-eular.1568","article-title":"OP0051 Lupus low disease activity state attainment in the phase 3 placebo-controlled TULIP long-term extension trial of anifrolumab","volume":"82","author":"Morand","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jval.2026.06.014_bib43","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3899\/jrheum.190259","article-title":"Effect of disease activity on organ damage progression in systemic lupus erythematosus: University of Toronto Lupus Clinic Cohort","volume":"48","author":"Urowitz","year":"2021","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.jval.2026.06.014_bib42","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard-2022-222487","article-title":"Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort","volume":"81","author":"Ugarte-Gil","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.jval.2026.06.014_bib44","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/art.24741","article-title":"Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus","volume":"61","author":"Nikpour","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.jval.2026.06.014_bib46","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1191\/096120399680411281","article-title":"Classification and definition of major flares in SLE clinical trials","volume":"8","author":"Petri","year":"1999","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.jval.2026.06.014_bib45","article-title":"Healthcare resource utilization and associated costs in patients with systemic lupus erythematosus diagnosed with lupus nephritis","volume":"15","author":"Bell","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jval.2026.06.014_bib53","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12955-015-0262-0","article-title":"Elicitation of health state utilities associated with varying severities of flares in systemic lupus erythematosus","volume":"13","author":"Pollard","year":"2015","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"10.1016\/j.jval.2026.06.014_bib54","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/09612033221146093","article-title":"The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States","volume":"32","author":"Bell","year":"2023","journal-title":"Lupus"},{"issue":"8","key":"10.1016\/j.jval.2026.06.014_bib47","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.21955","article-title":"Mortality in systemic lupus erythematosus","volume":"54","author":"Bernatsky","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.jval.2026.06.014_bib48","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13075-022-02756-3","article-title":"\u201cNot at target\u201d: prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study","volume":"24","author":"Kandane-Rathnayake","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.jval.2026.06.014_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000539","article-title":"Hospitalisation for systemic lupus erythematosus associates with an increased risk of mortality in Australian patients from 1980 to 2014: a longitudinal, population-level, data linkage, cohort study","volume":"8","author":"Raymond","year":"2021","journal-title":"Lupus Sci Med"},{"issue":"9","key":"10.1016\/j.jval.2026.06.014_bib50","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/09612033221107534","article-title":"Differential impact of disease activity and damage on health-related quality of life in patients with systemic lupus erythematosus","volume":"31","author":"Riaz","year":"2022","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.jval.2026.06.014_bib51","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/rheumatology\/keae120","article-title":"Lupus low disease activity state and organ damage in relation to quality of life in systemic lupus erythematosus: a cohort study with up to 11 years of follow-up","volume":"64","author":"Parodis","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.jval.2026.06.014_bib52","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1016\/S2665-9913(25)00022-0","article-title":"Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial","volume":"7","author":"Strand","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"11","key":"10.1016\/j.jval.2026.06.014_bib57","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1089\/jwh.2017.6334","article-title":"Impact of sex on systemic lupus erythematosus-related causes of premature mortality in the United States","volume":"26","author":"Falasinnu","year":"2017","journal-title":"J Womens Health (Larchmt)"},{"issue":"2","key":"10.1016\/j.jval.2026.06.014_bib58","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/acr.22938","article-title":"Disease outcomes in glucocorticosteroid-naive patients with systemic lupus erythematosus","volume":"69","author":"Sheane","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.jval.2026.06.014_bib59","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/acr.23867","article-title":"Association of achieving lupus low disease activity state fifty percent of the time with both reduced damage accrual and mortality in patients with systemic lupus erythematosus","volume":"72","author":"Sharma","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"10.1016\/j.jval.2026.06.014_bib60","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/acr.24086","article-title":"Treatment target in newly diagnosed systemic lupus erythematosus: the association of lupus low disease activity state and remission with lower accrual of early damage","volume":"72","author":"Floris","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.jval.2026.06.014_bib61","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/annrheumdis-2012-202443","article-title":"Annual direct medical cost of active systemic lupus erythematosus in five European countries","volume":"73","author":"Doria","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jval.2026.06.014_bib62","article-title":"Comparative assessment of different health utility measures in systemic lupus erythematosus","volume":"5","author":"Wang","year":"2015","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.jval.2026.06.014_bib63","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.healthpol.2018.12.003","article-title":"Health related quality of life aspects not captured by EQ-5D-5L: results from an international survey of patients","volume":"123","author":"Efthymiadou","year":"2019","journal-title":"Health Policy"},{"issue":"14","key":"10.1016\/j.jval.2026.06.014_bib64","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1177\/0961203318808593","article-title":"Fluctuation, invisibility, fatigue\u2014the barriers to maintaining employment with systemic lupus erythematosus: results of an online survey","volume":"27","author":"Booth","year":"2018","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.jval.2026.06.014_bib65","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s10067-023-06500-3","article-title":"An online survey of the Spanish Lupus Patient Association (FELUPUS): patient perceptions and experiences","volume":"42","author":"Salman-Monte","year":"2023","journal-title":"Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.jval.2026.06.014_bib66","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1177\/0961203317698594","article-title":"Burden of illness in systemic lupus erythematosus: results from a UK patient and carer online survey","volume":"26","author":"Kent","year":"2017","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.jval.2026.06.014_bib41","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/S2665-9913(19)30037-2","article-title":"Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. [Supplementary Appendix 1]","volume":"1","author":"Golder","year":"2019","journal-title":"Lancet Rheumatol"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526025349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526025349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:32:12Z","timestamp":1791826332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301526025349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":64,"alternative-id":["S1098301526025349"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2026.06.014","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modeling Systemic Lupus Erythematosus Treatment Cost-Effectiveness Based on a Novel Lupus Low Disease Activity State Treat-to-Target Approach","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2026.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}